Tetraarsenic Hexoxide Polymorph A Brain Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain cancer face challenges due to the brain-blood barrier, which hinders drug penetration, and existing therapies have limited effectiveness with significant side effects, necessitating a more potent and BBB-penetrable anticancer agent.
Innovation Solution
A pharmaceutical composition containing 99% or more of tetraarsenic hexoxide crystalline polymorph A (As4O6-a) is developed, prepared through a specific method involving repeated heating and cooling cycles with sodium chloride and arsenic trioxide, to enhance brain cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher concentration of anticancer drugs is administered to overcome the brain-blood barrier, then the anticancer effect is improved, but serious side effects in other organs occur
Solution Approach 1:
The patent applies local quality by using a specific crystalline polymorph form of tetraarsenic hexoxide (polymorph A with specific crystal structure and purity ≥99%) that exhibits selective penetration capability through the brain-blood barrier while maintaining lower systemic toxicity. This specific crystalline form demonstrates different biological properties compared to other polymorphs, enabling localized action in the brain with reduced harmful effects on other organs.
2Reliability
If surgical excision is performed for brain cancer, then treatment effectiveness is improved, but postoperative complications and risks increase
Solution Approach 1:
The patent extracts the essential anticancer function from surgical intervention by providing a chemotherapeutic agent (tetraarsenic hexoxide crystalline polymorph A) that can deliver tumor-killing effects through chemical means rather than physical removal. This approach extracts the therapeutic benefit of eliminating cancer cells while avoiding the invasive nature and associated risks of surgical excision, particularly for tumors in difficult-to-reach brain locations.
3Reliability
If complete excision of brain cancer is attempted, then tumor removal is improved, but the risk of postoperative complications becomes very high
Solution Approach 1:
The patent converts the limitation of the brain-blood barrier (which normally protects healthy brain tissue from harmful substances) into a beneficial feature by discovering that the specific crystalline polymorph A of tetraarsenic hexoxide can selectively penetrate this barrier while other forms cannot. This transforms what was previously seen as a protective obstacle into a selective delivery mechanism that benefits tumor treatment while sparing healthy tissue from excessive drug exposure.
4Reliability
If tetraarsenic hexoxide with different crystalline polymorph forms is used, then anticancer activity varies, but the treatment consistency and predictability worsen
Solution Approach 1:
The patent applies parameter changes by precisely controlling the crystalline polymorph form of tetraarsenic hexoxide to be polymorph A with specific crystallographic parameters and purity ≥99%. This specific parameter specification (crystalline structure, purity level) ensures consistent biological activity and reliable treatment outcomes, eliminating the variability that would result from using mixed or unspecified polymorph forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits brain cancer cell proliferation and metastasis, demonstrating superior treatment effects compared to previous tetraarsenic hexoxide forms, with excellent anticancer activity and reduced side effects by efficiently crossing the brain-blood barrier.
Implementation Method 1
a first step of heating sodium chloride at 100∼800°C, followed by cooling; a second step of placing arsenic trioxide (As 2 O 3 ) on the sodium chloride, followed by heating from 100°C to 1000°C in an airtight state and then cooling
Implementation Method 2
a third step of separating crystals crystallized in a filter bed
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~4
AI summary
The present invention relates to a pharmaceutical composition which is for preventing or treating brain cancer and includes at least 99% of a crystal polymorph of tetraarsenic hexoxide a(As406-a), and to a method for preparing same. A composition according to the present invention exhibits excellent cancer cell proliferation inhibition and metastasis inhibition effects, and thus may be usefully used as an anti-cancer agent.